CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
Alertgy non-invasive continuous glucose monitoring device (ANICGM)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04166032
NCT04166032N/ACompleted

Validation Study for the Alertgy Non-invasive Continuous Glucose Monitor

The Cleveland Clinic·interventional·Posted Nov 18, 2019·Updated Nov 9, 2021

In Brief

A clinical study evaluating Alertgy non-invasive continuous glucose monitoring device (ANICGM) for Type 2 Diabetes. Completed, enrolled 15 participants across 1 site.

Detailed Summary

Diabetes mellitus (DM) affects 30 million people in the United States. To achieve glucose control, most patients are prescribed glucose meters by their physicians. Obtaining glucose levels in this manner necessitates cleaning the fingers, attaching a lancet to a device (or simply using a lancet if a device is not available), pricking the finger with a lancet, placing a drop blood on a strip, and awaiting the readout that results after some chemical reactions. Thereafter, the lancet has to be disposed of in a safe receptacle and the finger has to be blotted to stop the blood from oozing. The anxiety, pain, and tedious process have led researchers to develop other means of checking glucose levels. There are now continuous glucose monitoring systems (CGMS) that entail inserting a subcutaneous sensor that sends readings through a transmitter. These CGMs may or may not need calibration with a fingerstick glucose reading, and the subcutaneous sensor still has to be changed every 10 -14 days. The Alertgy non-invasive continuous glucose monitor (ANICGM) is a device that does not entail any subcutaneous insertion of a sensor. It is strapped on to the wrist, and glucose readings are given based on subcutaneous signals. In 2001, a non-invasive device called Glucowatch Biographer was introduced that also involved subcutaneous signals without needing a subcutaneous insertion. However, for various reasons such as long calibration period and reading inaccuracies, the product did not take off. The ANICGM is a promising device that might overcome the limitations of existing and previous methods of non-invasive glucose measurement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsAlertgy

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 18, 2019
Enrollment StartNov 6, 2019
Primary CompletionFeb 4, 2020
Study CompletionMay 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.6 years ago

Interventions

Alertgy non-invasive continuous glucose monitoring device (ANICGM)device

Alertgy non-invasive continuous glucose monitoring device (ANICGM)